1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Wu Y, Sarkissyan M and Vadgama JV:
Epithelial-mesenchymal transition and breast cancer. J Clin Med.
5(pii): E132016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Cullen BR: MicroRNAs as mediators of viral
evasion of the immune system. Nat Immunol. 14:205–210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Chen LJ, Lim SH, Yeh YT, Lien SC and Chiu
JJ: Roles of microRNAs in atherosclerosis and restenosis. J Biomed
Sci. 19:792012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Esau C, Kang X, Peralta E, Hanson E,
Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, et
al: MicroRNA-143 regulates adipocyte differentiation. J Biol Chem.
279:52361–52365. 2004. View Article : Google Scholar : PubMed/NCBI
|
7
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Serpico D, Molino L and Di Cosimo S:
microRNAs in breast cancer development and treatment. Cancer Treat
Rev. 40:595–604. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Luo J, Wu J, Li Z, Qin H, Wang B, Wong TS,
Yang W, Fu QL and Lei W: miR-375 suppresses IGF1R expression and
contributes to inhibition of cell progression in laryngeal squamous
cell carcinoma. Biomed Res Int. 2014:3745982014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Shi ZC, Chu XR, Wu YG, Wu JH, Lu CW, Lü
RX, Ding MC and Mao NF: MicroRNA-375 functions as a tumor
suppressor in osteosarcoma by targeting PIK3CA. Tumour Biol.
36:8579–8584. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Shen Y, Zhou J, Li Y, Ye F, Wan X, Lu W,
Xie X and Cheng X: miR-375 mediated acquired chemo-resistance in
cervical cancer by facilitating EMT. PLoS One. 9:e1092992014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Yamaoka T and Itakura M: Development of
pancreatic islets (review). Int J Mol Med. 3:247–261.
1999.PubMed/NCBI
|
15
|
Elso C, Lu X, Weisner PA, Thompson HL,
Skinner A, Carver E and Stubbs L: A reciprocal translocation
dissects roles of Pax6 alternative promoters and upstream
regulatory elements in the development of pancreas, brain, and eye.
Genesis. 51:630–646. 2013.PubMed/NCBI
|
16
|
Luo J, Li H and Zhang C: MicroRNA-7
inhibits the malignant phenotypes of non-small cell lung cancer in
vitro by targeting Pax6. Mol Med Rep. 12:5443–5448. 2015.PubMed/NCBI
|
17
|
Meng B, Wang Y and Li B: Suppression of
PAX6 promotes cell proliferation and inhibits apoptosis in human
retinoblastoma cells. Int J Mol Med. 34:399–408. 2014.PubMed/NCBI
|
18
|
Cheng Q, Cao H, Chen Z, Ma Z, Wan X, Peng
R and Jiang B: PAX6, a novel target of miR-335, inhibits cell
proliferation and invasion in glioma cells. Mol Med Rep.
10:399–404. 2014.PubMed/NCBI
|
19
|
Li Y, Li Y, Liu Y, Xie P, Li F and Li G:
PAX6, a novel target of microRNA-7, promotes cellular proliferation
and invasion in human colorectal cancer cells. Dig Dis Sci.
59:598–606. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Shyr CR, Tsai MY, Yeh S, Kang HY, Chang
YC, Wong PL, Huang CC, Huang KE and Chang C: Tumor suppressor PAX6
functions as androgen receptor co-repressor to inhibit prostate
cancer growth. Prostate. 70:190–199. 2010.PubMed/NCBI
|
21
|
Meng Y, Zou Q, Liu T, Cai X, Huang Y and
Pan J: microRNA-335 inhibits proliferation, cell-cycle progression,
colony formation, and invasion via targeting PAX6 in breast cancer
cells. Mol Med Rep. 11:379–385. 2015.PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Hu A, Huang JJ, Xu WH, Jin XJ, Li JP, Tang
YJ, Huang XF, Cui HJ, Sun GB, Li RL and Duan JL: MiR-21/miR-375
ratio is an independent prognostic factor in patients with
laryngeal squamous cell carcinoma. Am J Cancer Res. 5:1775–1785.
2015.PubMed/NCBI
|
24
|
Jimenez L, Sharma VP, Condeelis J, Harris
T, Ow TJ, Prystowsky MB, Childs G and Segall JE: MicroRNA-375
suppresses extracellular matrix degradation and invadopodial
activity in head and neck squamous cell carcinoma. Arch Pathol Lab
Med. 139:1349–1361. 2015. View Article : Google Scholar : PubMed/NCBI
|
25
|
Costa-Pinheiro P, Ramalho-Carvalho J,
Vieira FQ, Torres-Ferreira J, Oliveira J, Gonçalves CS, Costa BM,
Henrique R and Jerónimo C: MicroRNA-375 plays a dual role in
prostate carcinogenesis. Clin Epigenetics. 7:422015. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Patnaik S, Mallick R, Kannisto E, Sharma
R, Bshara W, Yendamuri S and Dhillon SS: MiR-205 and MiR-375
microRNA assays to distinguish squamous cell carcinoma from
adenocarcinoma in lung cancer biopsies. J Thorac Oncol. 10:446–453.
2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Erbes T, Hirschfeld M, Rücker G, Jaeger M,
Boas J, Iborra S, Mayer S, Gitsch G and Stickeler E: Feasibility of
urinary microRNA detection in breast cancer patients and its
potential as an innovative non-invasive biomarker. BMC Cancer.
15:1932015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Wu X, Somlo G, Yu Y, Palomares MR, Li AX,
Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, et al: De novo sequencing
of circulating miRNAs identifies novel markers predicting clinical
outcome of locally advanced breast cancer. J Transl Med. 10:422012.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Ye XM, Zhu HY, Bai WD, Wang T, Wang L,
Chen Y, Yang AG and Jia LT: Epigenetic silencing of miR-375 induces
trastuzumab resistance in HER2-positive breast cancer by targeting
IGF1R. BMC Cancer. 14:1342014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Hong S, Noh H, Teng Y, Shao J, Rehmani H,
Ding HF, Dong Z, Su SB, Shi H, Kim J and Huang S: SHOX2 is a direct
miR-375 target and a novel epithelial-to-mesenchymal transition
inducer in breast cancer cells. Neoplasia. 16:279–290.e1-5. 2014.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Georgala PA, Carr CB and Price DJ: The
role of Pax6 in forebrain development. Dev Neurobiol. 71:690–709.
2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Hanson IM: PAX6 and congenital eye
malformations. Pediatr Res. 54:791–796. 2003. View Article : Google Scholar : PubMed/NCBI
|
34
|
Zong X, Yang H, Yu Y, Zou D, Ling Z, He X
and Meng X: Possible role of Pax-6 in promoting breast cancer cell
proliferation and tumorigenesis. BMB Rep. 44:595–600. 2011.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Huang BS, Luo QZ, Han Y, Li XB, Cao LJ and
Wu LX: microRNA-223 promotes the growth and invasion of
glioblastoma cells by targeting tumor suppressor PAX6. Oncol Rep.
30:2263–2269. 2013.PubMed/NCBI
|
36
|
Mayes DA, Hu Y, Teng Y, Siegel E, Wu X,
Panda K, Tan F, Yung WK and Zhou YH: PAX6 suppresses the
invasiveness of glioblastoma cells and the expression of the matrix
metalloproteinase-2 gene. Cancer Res. 66:9809–9817. 2006.
View Article : Google Scholar : PubMed/NCBI
|